Day 1 - Saturday, 2 March 2019

 8:30 AMOpening of the workshop 
 Session 1: Current controversies for cART use in women of child bearing potential and in pregnancy
Chairs: Catherine Hankins and Karoline Aebi-Popp
 08:45 AM

Clinical case: Researcher perspective
Tendani Gaolathe, MD - Botswana Harvard AIDS Institute Partnership, Botswana


09:15 AM

Clinical case: Community perspective
Lucy Wanjiku Njenga - Positive Young Women Voices, Kenya

 09:45 AM

Clinical case: Policy implications
Meg Doherty, MD, PhD - WHO, UK

 10:15 AM Discussion 
 10:30 AMGroup Picture 
 10:45 AMCoffee Break 
  Abstract-driven presentations 
 11:15 AM

INSTI exposure and neural tube defects –
data from antiretroviral pregnancy registry
Jessica Albano, PhD, MPH - Syneos Health, USA

 11:30 AM

Congenital anomalies in infants of Canadian women exposed to antiretrovirals including dolutegravir
Deborah Money, MD - UBC, Canada

 11:45 AM

Evaluation of neural tube defects after exposure to Raltegravir
during pregnancy

Hala Shamsuddin, MD - Merck, USA

 12:00 PMPanel discussion:  debaters, community, presenters 
  12:30 PMLunch
 Session 2: New drug delivery systems, are they right for women?
Chair: Sharon Walmsley
 01:30 PM

Invited lecture, focus on cabotegravir
Annemiek de Ruiter, MBBS FRCP, MD, ViiV Healthcare, UK

 02:00 PM

Emerging drug delivery systems for treatment and prevention of HIV

Kimberly Scarsi, PharmD, MS, University of Nebraska, USA

  Abstract-driven presentations
 02:30 PM

Clinical development strategy to inform dosing of antiretroviral drugs
in women: dolutegravir as a case study

Kimberly Adkison, PhD - Viiv Healthcare, USA

 2:45 PM

HIV risk and characteristics of women seeking PrEP
in a US demonstration project
Jill Blumenthal, MD - University of California, San Diago, USA

 03:00 PMDiscussion 
 03:15 PMCoffee Break 
 Session 3: Unique challenges of growing up with HIV
Chairs: Angelina Namiba and Teresia Otieno
 03:45 PM
Invited lecture: Unique challenges of growing up with HIV

Vanessa, CHIVA, UK
  Abstract-driven presentations 
 04:15 PMOptimizing HIV service delivery for young women who sell sex:
a discrete choice experiment
Sue Napierala, PhD, MPH - RTI International, USA
 04:30 PMHigh PrEP uptake among HIV-exposed women with pregnancy plans
in South Africa
Lynn Matthews, MD - University of Alabama at Birmingham, USA
 04:45 PMInnovative intervention for pregnant and breastfeeding adolescent mothers to enhance viral suppression in Homa Bay County, Kenya
Elizabeth Okoth (presented by N. Rakhmanina), MPH -
Elizabeth Glaser Pediatric AIDS Foundation, Kenya
 05:00 PMDiscussion 
 5:15 PMWelcome drinks and poster viewing session 1 
  Guided poster tour 1: ARV and pregnancy issues  
  Altered levels of bioactive lipids in HIV and cART-exposed pregnancy
Kayode Balogun 
  Double-Dose Levonorgestrel Implant Does Not Fully Overcome
Drug-Drug Interaction with Efavirenz

Kimbery Scarsi 
  Lopinavir (an HIV protease inhibitor) impairs uterine remodeling
during pregnancy

Smriti Kala 
  Adverse pregnancy outcomes in HIV-positive pregnant women
on ART in Kenya

Lisa Abuogi 
  Adoption of an HIV-neutral approach to pregnancy care
in San Francisco, California

Dominika Seidman 
  Early antenatal care visit as it relates to prevention of
mother to child transmission of HIV in sub-Saharan Africa

Adewale Adefila 
 07:00 PMNetworking dinner 

Day 2 - Sunday, 3 March 2019

 Session 4: Healthy aging with HIV for women
Chair: Margaret Johnson
 08:30 AM
Bone Health among women aging with HIV
Michael Yin, MD, New York State Psychiatric Institute & Columbia University, USA
 09:00 AM
Cardiac Muscle Health Among Women Aging with HIV
Markella Zanni, MD, MGH/Harvard Medical School, USA
 09:30 AM
Important Drug- Drug interactions in Women aging with HIV
Marta Boffito, MD, PhD, SSAT & Imperial College, Chelsea and Westminster Hospital, UK
 10:00 AMDiscussion 
 10:15 AMCoffee break and poster viewing session 2 
  Guided poster tour 2: ARV in women  
  Efficacy of two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) versus dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral naïve women: GEMINI studies subgroup analysis
Romina Quercia 
  Tenofovir Alafenamide vs Tenofovir DF in women: pooled analysis of 7 clinical trials
Melanie Thompson 
  Week 48 Safety and Efficacy of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Women in the BRIGHTE Study
Peter Ackerman 
  Efficacy and Safety of the Once-daily Darunavir/Cobicistat/
Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Single-tablet Regimen in Antiretroviral Treatment (ART)-experienced and ARTnaïve Women Living with HIV-1: EMERALD and AMBER Week 96 Results

Aimee Wilkin 
  Guided poster tour 3: Comprehensive care in women  
  Prevalence of Cervical Dysplasia in HIV-positive Women Versus
HIV-negative Women: The Case of Zambia

Aimee Rurangwa 
  Reflections on a specialist HIV menopause service
Roberta Brum 
  38% of child bearing women with HIV in the UK would like to breastfeed-Results from PACIFY study group
Farai Nyatsanza 
  Risk of hospitalisation according to gender and ethnicity among
people living with HIV in the modern ART era

Sophia Rein 
  Depression symptom trajectories among mothers
living with HIV in rural Uganda

Itziar Familiar 
  Development and piloting of a scale to measure trauma- and
violence-aware principles of HIV care and practice for women
living with HIV in Metro Vancouver, Canada

Kathleen Deering 
 Session 5: Research in women and HIV - 1
Chairs:  Markella Zanni and Patricia Vasquez
Abstract-driven presentations
 11:30 AMNon-Vaccine Oncogenic HPV Persistence Among
HPV-Vaccinated Women Living with HIV

Elisabeth McClymont - University of British Columbia, Canada
 11:45 AMDolutegravir pharmacokinetics during pregnancy and postpartum
Angela Colbers, PhD - Radboud University Medical Center, The Netherlands
 12:00 AMIntimate Partner Violence, Depression, and Mortality among a Cohort
of Women living with HIV Marginalized by Socio-structural Inequities
in Vancouver, Canada

Kalysha Closson - University Of British Columbia, Canada
  12:15 AMVaginal microbiome and associations with tenofovir diphosphate and lamivudine triphosphate in cervical tissues of Ugandan women
Melanie Nicol, PharmD, PhD - University of Minnesota, USA
 12:30 PMLunch 
 Session 6: HIV cure research - considerations for women
Chair: Natella Rakhmanina
 01:30 PM
HIV Cure: Where have we been, where are we going?
Daniel Kuritzkes, MD, Harvard Medical School, USA
 02:00 PM

Invited lecture:  Focus on women
Jintanat Ananworanich, MD, PhD,

US Military HIV Research Program, USA

  Abstract-driven presentation 
 02:30 PMWomen’s involvement in clinical research: Women included
in Dolutegravir clinical trials versus collaborative studies

Romina Quercia, MD, PhD, MPH - ViiV Healthcare, UK
 02:45 PMDiscussion 
 03:00 PMClosing of the workshop